Skip to content

VITASPRING BIOMEDICAL CO., LTD.: 10-Q filed 2026-06-17

What VITASPRING BIOMEDICAL CO., LTD. reported in its quarterly report filed 2026-06-17 (fiscal Q2 2026): 31 published measures, 88 facts as tagged in accession 0001640334-26-001075.

This filing

Form
10-Q (quarterly report)
Filed
2026-06-17
Fiscal period
fiscal Q2 2026
Accession
0001640334-26-001075 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VITASPRING BIOMEDICAL CO., LTD. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-07-3117,020USD
At 2025-01-3114,378USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-07-314,223,606USD
At 2025-01-314,029,578USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-07-31-4,206,586USD
At 2025-04-30-4,095,741USD
At 2025-01-31-4,015,200USD
At 2024-07-31-3,703,249USD
At 2024-04-30-3,525,803USD
At 2024-01-31-3,350,189USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-07-310USD
At 2025-01-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-05-01 to 2025-07-31-110,845USD92
2025-02-01 to 2025-07-31-191,386USD181
2025-02-01 to 2025-04-30-80,541USD89
2024-05-01 to 2024-07-31-218,662USD92
2024-02-01 to 2024-07-31-435,493USD182
2024-02-01 to 2024-04-30-216,831USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-02-01 to 2025-07-31-1,973USD181
2024-02-01 to 2024-07-31-6,444USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-05-01 to 2025-07-310USD92
2025-02-01 to 2025-07-310USD181
2024-05-01 to 2024-07-310USD92
2024-02-01 to 2024-07-310USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-02-01 to 2025-07-312,500USD181
2024-02-01 to 2024-07-3111,956USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-07-31-5,472,889USD
At 2025-01-31-5,281,503USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-05-01 to 2025-07-31207,030,030shares92
2025-02-01 to 2025-07-31207,030,030shares181
2024-05-01 to 2024-07-31207,030,030shares92
2024-02-01 to 2024-07-31207,030,030shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-05-01 to 2025-07-310USD/shares92
2025-02-01 to 2025-07-310USD/shares181
2024-05-01 to 2024-07-310USD/shares92
2024-02-01 to 2024-07-310USD/shares182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-05-01 to 2025-07-3111,778USD92
2025-02-01 to 2025-07-3123,172USD181
2024-05-01 to 2024-07-310USD92
2024-02-01 to 2024-07-310USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-07-319,127USD
At 2025-01-3114,106USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-02-01 to 2025-07-310USD181
2024-05-01 to 2024-07-3141,216USD92
2024-02-01 to 2024-07-3182,433USD182
2024-02-01 to 2024-04-3041,217USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-05-01 to 2025-07-31-99,067USD92
2025-02-01 to 2025-07-31-168,214USD181
2024-05-01 to 2024-07-31-218,662USD92
2024-02-01 to 2024-07-31-435,493USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-07-317,893USD
At 2025-01-31272USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-07-314,223,606USD
At 2025-01-314,029,578USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-07-312,411,000USD
At 2025-01-312,411,000USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-05-01 to 2025-07-3199,067USD92
2025-02-01 to 2025-07-31168,214USD181
2024-05-01 to 2024-07-31218,662USD92
2024-02-01 to 2024-07-31435,493USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-07-31207,030,030shares
At 2025-01-31207,030,030shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-07-31799USD
At 2025-01-31272USD
At 2024-07-315,525USD
At 2024-01-3113USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-07-311,245,600USD
At 2025-01-311,245,600USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2025-07-31-4,206,586USD
At 2025-01-31-4,015,200USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-07-3172,997USD
At 2025-01-3172,997USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-07-3153,421USD
At 2025-01-3148,442USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-05-01 to 2025-07-31-99,067USD92
2025-02-01 to 2025-07-31-168,214USD181
2024-05-01 to 2024-07-31-218,662USD92
2024-02-01 to 2024-07-31-435,493USD182

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-02-01 to 2025-07-31-191,386USD181
2024-02-01 to 2024-07-31-435,493USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-02-01 to 2025-07-314,979USD181
2024-02-01 to 2024-07-314,979USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-02-01 to 2025-07-310USD181
2024-02-01 to 2024-07-310USD182

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-02-01 to 2025-07-310USD181
2024-02-01 to 2024-07-310USD182

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-02-01 to 2025-07-310USD181
2024-02-01 to 2024-07-3196,075USD182

Inspect the source

Entity
VITASPRING BIOMEDICAL CO., LTD. / CIK 0001697884
Captured
2026-09-21T17:23:44.772Z
SEC response SHA-256
ee15de6dda3aedafc6c6b7ee7d9d21edb5e0091bf01dcbaec55b3fe460e6f43a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001697884.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))